ArticleTranslational cancer research2026
Potential role of PPARGC1A in linking ulcerative colitis to colorectal cancer: a novel prognostic biomarker and therapeutic target.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rising incidence of ulcerative colitis (UC) worldwide significantly increases the risk of ulcerative colitis-associated colorectal cancer (UC-CRC). Although chronic inflammation drives the inflammation-dysplasia-carcinogenesis sequence, the early hit molecular factors remain poorly understood. This study aims to identify potential biomarkers and mechanisms from UC to UC-CRC. Methods: Multi-omics integration was performed using multiple database. We adopted an R-based workflow for differential expression analysis, functional enrichment analysis, and co-expression network analysis, gene set enrichment analysis (GSEA), and immune cell infiltration analysis. Single-cell RNA sequencing verified cell-specific expression and perturbed genes by simulated knockout (KO) analysis. Clinical significance was evaluated by Kaplan-Meier and Cox regression analysis. Drug sensitivity was then predicted based on the Drug Sensitivity in Cancer (GDSC) database. Results: PPARGC1A was significantly downregulated in intestinal epithelial cells of both UC and colorectal cancer (CRC) patients. Its expression remained low throughout the malignant transformation process, serving as a possible early hit factor. Low expression was associated with poor overall survival (OS) and malignant phenotypes, such as EMT, mTORC1 signaling pathway, while high expression maintained metabolic homeostasis. Additionally, PPARGC1A deficiency was associated with an immunosuppressive microenvironment. Drug sensitivity analysis and molecular docking provides a theoretical basis for subsequent chemical optimization. Conclusions: PPARGC1A may serve as potential early-hit factor for UC-CRC transformation. Suggesting the PPARGC1A axis represents a potential target for early warning and personalized management of patients at high risk of UC-CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.